Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer

Figures & data

Table 1 Response rate and tumor cell characteristics of ABC treated with bevacizumab plus nab-paclitaxel^52,53

	Response
	Total patients	CR (n)	ORR (%)	SD (n)	CB (%)	PD
Er-pos or PgR-pos	23	1	43.5%	4	60.9%	9
Er-neg or PgR-neg	10	2	60%	1	70%	3
Her-2-neg	21	2	47.6%	1	52.4%	10
Her-2-pos	12	1	50.%	4	83.3%	2
Triple neg	4	1	75%	0	75%	1
Total	33	3	48.5%	5	63.9%	12

Abbreviations: CR, complete response; ORR, overall response rate; PD, progressive disease; SD, stable disease; PgR, progesterone receptor; ER, estrogen receptor; CB, clinical benefit.

Table 2 Adverse events (all grades) reported in either group

Adverse events	Nab-paclitaxel	CrEL paclitaxel	p
	% of pts	% of pts
Alopecia	90	93
Sensory neuropathy	70	55	<0.001
Fatigue	45	35
Neutropenia	30	50
Arthralgia	30	29
Myalgia	25	28
Nausea	27	20
Diarrhea	23	15
Hyperglycemia	1	7	0.003
Hypersensitivity reactions	<1	2

Table 3 Adverse events in patients >65 years old in the nab-paclitaxel group compared with the CrEL-paclitaxel group

Adverse events	Nab-paclitaxel	CrEL paclitaxel
	% of pts	% of pts
Neutropenia	23	59
Leukopenia	10	31
Nausea	20	38
Hyperglycemya	0	19
Flushing	0	16

Table 4 Summary of phase II clinical studies of novel taxane formulations

Author	Regimen	No. patients	Outcome					Toxicity
			RR%	TTP (mos)	PFS%	MS	OS	Grade 3–4 (%)
Ibrahim et al^Citation50	Nab-paclitaxel 300 mg/m^2 q3w	63	48	26,6			63,6	Neutropenia g4 (24) Neuropathy g3 (11)
Blum et al^Citation51	Nab-paclitaxel 100 mg/m^2 w	66	20 (RP)					Neutropenia g4 (8) Nausea g4 (4,5) Infection g4 (4,5)
Roy et al^Citation30	Nab-paclitaxel 125 mg/m^2 w + Gemcitabine 1000 mg/m^2 w	50	50		60		92	Neutropenia g4 (12) Neutropenia g3 (43)
Link et al^Citation52	Nab-paclitaxel plus Bevacizumab	40	48,5	4,2
Blum et al^Citation55	Nab-paclitaxel 100 mg/m^2 w	181	14		3	9,2		Neutropenia g4 (<5)
	Nab-paclitaxel 125 mg/m^2 w		16		3,5	9,1
Schwartzberg et al^Citation56	Nab-paclitaxel 125 mg/m^2 w + Capecitabine 825 mg/m^2	50	47,5					Neutropenia g4 (20) Fatigue g4 (20)

Abbreviations: TTP, time to progression; MS, median survival; OS overall survival; PFS, progression free survival; RR, response rate; q3w, every 3 weeks; mos, months; w, week; MS, median survival.

Table 5 Summary of phase II clinical studies of novel taxane formulations

Author	Regimen	No. patients	Outcome			Toxicity
			RR%	TTP (mos)	PFS (mos)	Grade 3–4 (%)
Gradishar et al^Citation57	Nab-paclitaxel 260 mg/m^2 q3w vs Paclitaxel 175 mg/m^2 q3w	229 225	33 19	23 16,9	25,7 25,2	Neutropenia g4 (9) Neuropathy g3 (10) Neutropenia g4 (22) Neuropathy g3 (2)
Gradishar et al^Citation58	Nab-paclitaxel 300 mg/m^2 q3w vs Nab-paclitaxel 100 mg/m^2 q3/4w vs Nab-paclitaxel 150 mg/m^2 q3/4w vs Docetaxel 100 mg/m^2 q3/4w	76 76 74 74	33 58 62 36		10,6 9,3 9,2 7,3	Neutropenia g4 (4) Neuropathy g3 (14) Neutropenia g4 (3) Neuropathy g3 (7) Neutropenia g4 (7) Neuropathy g3 (12) Neutropenia g4 (74)

Abbreviations: TTP, time to progression; PFS, progression free survival; RR, response rate; q3w, every 3 weeks; mos, months; w, week; MS, median survival; q3w, every 3 weeks; q3/4 w, every 3 or 4 weeks; mos, months; w, week.

LinkJSWaismanJRNguyenBBevacizumab and albumine-bound paclitaxel treatment in metastatic breast cancerClin Breast Cancer20071077978318021479

 PubMed Web of Science ®Google Scholar

GradisharWCortesJClinical efficacy and emerging therapeutic utilization of novel taxanesEJC Supplements20081061221

 Google Scholar

IbrahimNKSamuelsBPageRDovalDPatelKMRaoSCMulticenter Phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancerJ Clin Oncol200523256019602616135470

 PubMed Web of Science ®Google Scholar

BlumJLSavinMAEdelmanGPippenJERobertNSandbachJLong term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel [abstract]J Clin Oncol20042214 SupplAbstract 543

 Google Scholar

RoyVLaplantBRGrossGGfor the North Central Cancer Treatment GroupPhase II trial of weekly nab (nanoparticle albuminbound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (NO531)Ann Oncol20092044945319087987

 PubMed Web of Science ®Google Scholar

BlumJLSavinMAEdelmanGPippenJERobertNJGeisterBVPhase II study of weekly albumin – bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanesClin Breast Cancer200711580586

 Web of Science ®Google Scholar

SchwartzbergLSArenaFMintzerDPhase II trial of nanoparticle albumin-bound paclitaxel (ABX) + capecitabine (XEL) in first line treatment of metastatic breast cancer (MBC):interim results [abstract]Breast Cancer Res Treat2006100Suppl 11096

 Google Scholar

GradisharWJTjulandinSDavidsonNShawHDesaiNBharPPhase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancerJ Clin Oncol200523317768777116204007

 PubMed Web of Science ®Google Scholar

GradisharWKrasnojonDCheporovSManikhasGClawsonAHawkinsMJRandomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC)J Clin Oncol200725Suppl18S

 Google Scholar